Trials / Completed
CompletedNCT00656461
Phase 1 Study of MKC-1 in Patients With Advanced Cancer
Phase 1 Study of MKC-1 in Patients With Advanced or Metastatic Solid Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- CASI Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label study to determine the highest dose of MKC-1 that may be administered daily on a continuous basis for patients with advanced or refractory solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MKC-1 | 30 mg and 100 mg capsules, dosed BID daily on a continuous schedule |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2009-07-01
- Completion
- 2009-11-01
- First posted
- 2008-04-11
- Last updated
- 2009-11-25
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00656461. Inclusion in this directory is not an endorsement.